Cancer Therapeutics: Experimental and Clinical Agents by Beverly A. TeicherCancer Therapeutics: Experimental and Clinical Agents by Beverly A. Teicher

Cancer Therapeutics: Experimental and Clinical Agents

EditorBeverly A. Teicher

Paperback | November 19, 2010

Pricing and Purchase Info

$338.96 online 
$375.95 list price save 9%
Earn 1695 plum® points
Quantity:

In stock online

Ships free on orders over $25

Not available in stores

about

This comprehensive review of existing and potential anticancer drugs and therapies by leading researchers from academia, government laboratories, and pharmaceutical companies offers essential insight into what has been accomplished and where the experimental therapy of cancer is going. The authoritative contributors illuminate the current status of the major molecules of cancer treatment, ranging from the nitrogen mustards through platinum complexes to interferons, cytokines, growth factors and their inhibitors, and on to immunotoxins, antisense oligonucleotides, and gene therapy. A companion volume by the same editor (Anticancer Drug Development Guide: Preclinical and Clinical Screening and Approval) details the processes by which new anticancer drugs are approved. These two volumes in the Cancer Drug Discovery and Development series reveal how and why molecules become anticancer drugs and thus offer a blueprint for the present and the future of the field.
Title:Cancer Therapeutics: Experimental and Clinical AgentsFormat:PaperbackDimensions:463 pages, 10 × 7.01 × 0 inPublished:November 19, 2010Publisher:Humana PressLanguage:English

The following ISBNs are associated with this title:

ISBN - 10:1617370460

ISBN - 13:9781617370465

Look for similar items by category:

Reviews

Table of Contents

Part I. Cytotoxic Agents: Old and New. Nitrogen Mustards, Gerald J. Goldenberg and Malcolm J. Moore. Phosphoramide and Oxazaphosphorine Mustards, Joel E. Wright. Development of the Nitrosoureas, David B. Ludlum. Platinum Complexes, Lloyd R. Kelland. Anthracyclines, Trevor W. Sweatman and Mervyn Israel. Topoisomerase I Inhibitors, Beppino C. Giovanella. DNA Topoisomerase II Inhibitors, Yves Pommier. The Taxoids, Marie-Christine Bissery and François Lavelle. Sequence-Selective Groove Binders, Franco Zunino and Giovanni Capranico. Bis-Naphthalimides: Synthesis and Preclinical Evaluation, Cynthia A. Romerdahl and Miguel F. Braña. Part II. Newer Strategies and Targets. The Enediynes, Nina Felice Schor. Matrix Metalloproteinase Inhibitors, William G. Stetler-Stevenson. Interferons and Other Cytokines, Jill A. Hendrzak and Michael J. Brunda. Discovery of TNP-470 and Other Angiogenesis Inhibitors, Donald E. Ingber. Antisense Oligonucleotides, Stanley T. Crooke. Growth Factors and Growth Factor Inhibitors, Edward A. Sausville and Dan L. Longo. Immunoconjugates, Walter A. Blättler, Ravi V. J. Chari, and John M. Lambert. A Case for ras Targeted Agents as Antineoplastics, Judith S. Sebolt-Leopold. Gene Therapy, Peter I. Schrier and Susanne Osanto. Index.

Editorial Reviews

"...extremely readable...excellent treatment of drugs such as naphthalimides...Each chapter is succinct and well-written." -Cancer Forum"...a most important source of literature for all those who are involved in basic cancer research and in the clinical care of cancer patients in different fields of medicine." -Haematologia